| Followers | 35 |
| Posts | 2236 |
| Boards Moderated | 0 |
| Alias Born | 10/18/2019 |
Wednesday, April 27, 2022 8:46:01 AM
Hbpainter, you asked if UCLA does gbm research that does not involve the dendritic vaccine. (If I am sure about that)
If you believe Dr. Liau the answer is obviously yes they do much research and clearly some programs do not use the vaccine. Watch the first of the ihub links to ucla presentations 'perspectives on glioblastoma' and Dr. Liau talks of their 3 SPORE grant programs (specialized program of research excellence) and program 1 is the vaccine+ check point inhibitor + polyICLC+CSFR1, program 2 is on EGFR resistance and altered metabolic state and getting the bad cells to undergo apoptosis, program 3 is on radiation therapy. Start watching at minute 41 and Liau talks for 10 minutes on these research programs, #1 clearly uses the vaccine plus other treatments and Dr. Liau is very involved in this program #1. Programs 2 and 3 do not involve the vaccine as the UCLA researchers are looking at all sorts of treatment approaches. She also speaks for a moment on research by Dr Cloughesy published in 'Nature' that did not involve the vaccine but looked at timing of treatment with a checkpoint inhibitor - neoadjuvant administration of pd1 made a statically significant difference- this did not involve the vaccine but probably is part of the background research to SPORE program #1 using multiple treatment agents including vaccine.
The slides in this particular presentation are not easy to read but imo Liau's discussion is very informative on some of the UCLA research programs. The SPORE programs slide is easier to see in some of Liau's other presentations and I believe a screen shot has been posted in one of the messages on ihub.
The short answer is yes imo UCLA is doing other GBM research programs that do not use dcvax-l as well as research that does use the vaccine
Good luck
If you believe Dr. Liau the answer is obviously yes they do much research and clearly some programs do not use the vaccine. Watch the first of the ihub links to ucla presentations 'perspectives on glioblastoma' and Dr. Liau talks of their 3 SPORE grant programs (specialized program of research excellence) and program 1 is the vaccine+ check point inhibitor + polyICLC+CSFR1, program 2 is on EGFR resistance and altered metabolic state and getting the bad cells to undergo apoptosis, program 3 is on radiation therapy. Start watching at minute 41 and Liau talks for 10 minutes on these research programs, #1 clearly uses the vaccine plus other treatments and Dr. Liau is very involved in this program #1. Programs 2 and 3 do not involve the vaccine as the UCLA researchers are looking at all sorts of treatment approaches. She also speaks for a moment on research by Dr Cloughesy published in 'Nature' that did not involve the vaccine but looked at timing of treatment with a checkpoint inhibitor - neoadjuvant administration of pd1 made a statically significant difference- this did not involve the vaccine but probably is part of the background research to SPORE program #1 using multiple treatment agents including vaccine.
The slides in this particular presentation are not easy to read but imo Liau's discussion is very informative on some of the UCLA research programs. The SPORE programs slide is easier to see in some of Liau's other presentations and I believe a screen shot has been posted in one of the messages on ihub.
The short answer is yes imo UCLA is doing other GBM research programs that do not use dcvax-l as well as research that does use the vaccine
Good luck
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
